Cascading adoptive cell therapy for metastatic melanoma

Area of Science:

• Oncology
• Immunotherapy

Background:

• Adoptive tumor-infiltrating lymphocytes (TILs) therapy is effective for advanced melanoma but often requires intensive preconditioning (chemotherapy/irradiation).
• Preconditioning can cause severe side effects, particularly in elderly patients.
• Alternative methods to enhance TILs efficacy while minimizing toxicity are needed.

Observation:

• A patient with metastatic melanoma underwent sequential treatment: local tumor resection, followed by adoptive cytokine-induced killer (CIK) cells infusion, and then TILs infusion.
• This cascading adoptive cell therapy regimen was administered without intensive preconditioning.
• The patient experienced a complete response to the treatment.

Findings:

• Sequential administration of CIK cells followed by TILs infusion resulted in a complete response in a patient with metastatic melanoma.
• The combined therapy was well-tolerated, suggesting reduced toxicity compared to traditional preconditioning methods.
• Pretreatment with CIK cells may create a more favorable immune environment for subsequent TILs therapy.

Implications:

• This case suggests that CIK cell pretreatment can enhance the efficacy of TILs therapy for metastatic melanoma.
• Sequential adoptive cell therapy offers a potentially safer and effective alternative to conventional preconditioning regimens.
• This approach may improve treatment outcomes for patients with advanced melanoma, especially those who are elderly or frail.